Show simple item record

Recombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: immunological studies.

dc.contributor.authorGhosh, Anna K
dc.contributor.authorMellor, M
dc.contributor.authorPrendiville, Joseph A
dc.contributor.authorThatcher, Nick
dc.date.accessioned2010-07-21T16:14:22Z
dc.date.available2010-07-21T16:14:22Z
dc.date.issued1990-03
dc.identifier.citationRecombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: immunological studies. 1990, 61 (3):471-4 Br. J. Canceren
dc.identifier.issn0007-0920
dc.identifier.pmid2328217
dc.identifier.urihttp://hdl.handle.net/10541/108117
dc.description.abstractNatural killer (NK) cell activity and lymphokine activated killer (LAK) cell cytotoxicity were measured in patients receiving recombinant interleukin 2 (rIL-2) and flavone acetic acid (FAA) for treatment of progressing metastatic melanoma. NK activity was increased in 23 of 26 patients and LAK activity induced in 13 of 26 patients. However, levels of cytotoxicity in the present study were not significantly greater than a previous study using rIL-2 alone. LAK cell precursors demonstrated by in vitro incubation of pretreatment lymphocytes with IL-2 and subsequent cytotoxicity were no different in the patients compared to normal controls. Analysis of cell surface phenotypes failed to reveal any significant changes in the cell populations examined, including IL-2R and Leu 19. Although five patients had tumour response, one being complete, there was no correlation with the immunological parameters examined.
dc.language.isoenen
dc.subject.meshAdjuvants, Immunologic
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshCytotoxicity, Immunologic
dc.subject.meshDrug Evaluation
dc.subject.meshFemale
dc.subject.meshFlavonoids
dc.subject.meshHumans
dc.subject.meshInterleukin-2
dc.subject.meshKiller Cells, Lymphokine-Activated
dc.subject.meshKiller Cells, Natural
dc.subject.meshMale
dc.subject.meshMelanoma
dc.subject.meshRecombinant Proteins
dc.titleRecombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: immunological studies.en
dc.typeArticleen
dc.contributor.departmentImmunology Laboratory, Paterson Institute for Cancer Research, Manchester, UK.en
dc.identifier.journalBritish Journal of Canceren
html.description.abstractNatural killer (NK) cell activity and lymphokine activated killer (LAK) cell cytotoxicity were measured in patients receiving recombinant interleukin 2 (rIL-2) and flavone acetic acid (FAA) for treatment of progressing metastatic melanoma. NK activity was increased in 23 of 26 patients and LAK activity induced in 13 of 26 patients. However, levels of cytotoxicity in the present study were not significantly greater than a previous study using rIL-2 alone. LAK cell precursors demonstrated by in vitro incubation of pretreatment lymphocytes with IL-2 and subsequent cytotoxicity were no different in the patients compared to normal controls. Analysis of cell surface phenotypes failed to reveal any significant changes in the cell populations examined, including IL-2R and Leu 19. Although five patients had tumour response, one being complete, there was no correlation with the immunological parameters examined.


This item appears in the following Collection(s)

Show simple item record